ICER will assess the comparative clinical effectiveness and value of treatments for acute migraine, including:
- Two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan)
- A 5-HT1f agonist lasmiditan (Eli Lilly).
All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019.
Date of review: January 2020
For questions, please contact Ellie Adair, Deputy Chief Operating Officer, at firstname.lastname@example.org.
Sheraton Suites Chicago O’Hare
6501 Mannheim Road
Rosemont, IL 60018
The Midwest CEPAC will convene to review ICER's assessment of acute migraine treatments.